TTC Logo
     Molecular Pathology of Bladder Cancer
     About        Contact
Home•  Compounds•  Expert Opinion•  Trial Analysis•  Pathways•  Diseases•  Workspace • TOUR smartlink Bookmark and Share

Welcome to CuraBase® - The Curated and Collaborative Cancer Database

Click Here to Learn More about CuraBase®

signup

 
 

Access to CuraBase® is free-of-charge for users in Academia or Non-Profit Organizations.

Click Here To Register 

 

Region Incidence Overall Incidence Males Incidence Females Deaths Overall Deaths Males Deaths Females
USA 70530 52760 17770 14680 10410 4270
 
Source: American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010

Affected Protein Pathway Sub-Type Ethnicity Stage Frequency (%) Gene Amplification Activating Mutation Inactivating Mutation Deletion Promoter Hypermethylation Comment  
AKT1 PI3-Kinase Signaling
2.7%
ErbB-2 (Her2/neu) Receptor Tyrosine Kinase Signaling
transitional cell carcinoma (TCC) of urinary bladder 6%
ErbB-2 (Her2/neu) Receptor Tyrosine Kinase Signaling
transitional cell carcinoma (TCC) of urinary bladder 60% protein overexpression by IHC
FGFR-3 36 - 54% more frequent in low grade tumors
HRAS (H-Ras Farnesyl-Transferase) 4%
KRAS Ras Signal Transduction Pathway
7%
p14ARF (CDKN2A) p53 Tumor Suppressor Pathway
transitional cell carcinoma 43%
p16INK4a (CDKN2A) Cell Cycle Regulation
transitional cell carcinoma 23%
p16INK4a (CDKN2A) Cell Cycle Regulation
transitional cell carcinoma 60%
Pi3-kinase PI3-Kinase Signaling
13 - 27% associated with low-grade tumors:
PTEN PI3-Kinase Signaling
8% absence of expression
TSC1 PI3-Kinase Signaling
16%

Click Here For Clinical Trials in in CuraBase®
      CANCER.GOV PDQ® - Standard Treatments for Bladder Cancer